Birchview Capital, LP Biohaven Pharmaceutical Holding CO Ltd. Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in Biohaven Pharmaceutical Holding CO Ltd. stock. As of the latest transaction made, Birchview Capital, LP holds 7,365 shares of BHVN stock, worth $270,000. This represents 0.34% of its overall portfolio holdings.
Number of Shares
7,365
Previous 7,365
-0.0%
Holding current value
$270,000
Previous $255,000
44.31%
% of portfolio
0.34%
Previous 0.25%
Shares
7 transactions
Others Institutions Holding BHVN
# of Institutions
11Shares Held
792KCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL710KShares$26 Million17.51% of portfolio
-
Eaton Vance Management Boston, MA35.9KShares$1.32 Million0.01% of portfolio
-
S. Muoio & Co. LLC New York, NY19KShares$695,8063.79% of portfolio
-
Agf Investments LLC Boston, MA11.6KShares$423,7890.16% of portfolio
-
Brevan Howard Capital Management LP St. Helier, Y96.52KShares$239,1330.0% of portfolio
About Biohaven Pharmaceutical Holding Co Ltd.
- Ticker BHVN
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,645,000
- Market Cap $2.63B
- Description
- Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...